Last reviewed 2026-04-23 · How we verify

SKP-0141

SKP-0141 is a recombinant human albumin fusion protein designed to enhance hemostasis and reduce bleeding in patients with coagulation disorders.

SKP-0141 is a recombinant human albumin fusion protein designed to enhance hemostasis and reduce bleeding in patients with coagulation disorders. Used for Hemophilia or other inherited bleeding disorders.

At a glance

Mechanism of action

SKP-0141 functions as a procoagulant agent that promotes blood clotting through albumin-mediated delivery of clotting factors or direct enhancement of the coagulation cascade. The albumin fusion approach is intended to improve pharmacokinetics and reduce immunogenicity while maintaining hemostatic efficacy in bleeding disorders.

Approved indications

• Hemophilia or other inherited bleeding disorders

Common side effects

No common side effects on file.

Key clinical trials

• An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.